MWM
CLVS

Meridian Wealth Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Meridian Wealth Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,200
Closed -$236K – 207
2018
Q2 		$236K Buy
+5,200
New +$253K 0.11% 159

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Meridian Wealth Management's CLVS Position: Q3 2018 in Review

Meridian Wealth Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 5,200 shares — an estimated $236K sold.

Meridian Wealth Management first reported a position in CLVS in Q2 2018 and held it in 1 quarter. The position peaked at $236K in Q2 2018. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

  • Meridian Wealth Management reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
  • Meridian Wealth Management sold 5,200 Clovis Oncology, Inc. shares in Q3 2018, an estimated $236K.
  • Meridian Wealth Management first reported a position in Clovis Oncology, Inc. in Q2 2018 and held it in 1 quarter.
  • Meridian Wealth Management's Clovis Oncology, Inc. position peaked at $236K in Q2 2018.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Meridian Wealth Management's 13F filing for Q3 2018, filed 19 Oct 2018.